Q-omics provides the consensus-scored NPTXR profile across patient tissues and cancer cell-line models. NPTXR expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NPTXR is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, NPTXR RNA expression shows 18,593 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, THCA, and TGCT as cancer lineages where NPTXR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPTXR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPTXR survival associations across molecular data types. NPTXR RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPTXR RNA expression–survival associations across cancer types. High NPTXR expression shows unfavorable associations in MESO, KIRC, ACC and UCEC, but favorable associations in CESC and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for NPTXR RNA expression.
This table summarizes NPTXR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for NPTXR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPTXR shows lower tumor expression in KIRC and BLCA and higher tumor expression in THCA, KIRP, CHOL and LIHC. The THCA box plot shows higher NPTXR RNA expression in tumor versus normal tissue (log2 FC = +1.467, t-test p < 0.001).
This table shows molecular features associated with NPTXR in patient tissues and cancer cell lines. In patient samples, NPTXR shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NPTXR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
